As WHO has noted, the development of rapid and simple to use assays is technically readily achievable. Their commercial price is expected to be less costly than conventional PCR tests. Biomarkers already exist. No significant technical hurdles stand in the way.
Further progress and outstanding needs will be discussed during a WHO expert consultation on innovative Ebola diagnostic tests to be held in Geneva in December.